RT Journal Article SR Electronic T1 Population Genetics Analysis of SLC3A1 and SLC7A9 Revealed the Etiology of Cystine Stone May Be More Than What Our Current Genetic Knowledge Can Explain JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.05.09.23289733 DO 10.1101/2023.05.09.23289733 A1 Wu, Chen-Han Wilfred A1 Badreddine, Jad A1 Chang, Joshua A1 Huang, Yu-Ren Mike A1 Kim, Fernando J. A1 Wild, Trevor A1 Tsai, Anne A1 Meeks, Naomi A1 Da Silva, Rodrigo Donalisio A1 Molina, Wilson R. A1 Schumacher, Fredrick R. YR 2023 UL http://medrxiv.org/content/early/2023/05/10/2023.05.09.23289733.abstract AB Background Cystine stone is a Mendelian genetic disease caused by SLC3A1 or SLC7A9. In this study, we aimed to estimate the genetic prevalence of cystine stones and compare it with the clinical prevalence to better understand the disease etiology.Methods We analyzed genetic variants in the general population using the 1000 Genomes project and the Human Gene Mutation Database to extract all SLC3A1 and SLC7A9 pathogenic variants. All variants procured from both databases were intersected. Pathogenic allele frequency, carrier rate, and affected rate were calculated and estimated based on Hardy-Weinberg equilibrium.Results We found that 9 unique SLC3A1 pathogenic variants were carried by 26 people and 5 unique SLC7A9 pathogenic variants were carried by 12 people, all of whom were heterozygote carriers. No homozygote, compound heterozygote, or double heterozygote was identified in the 1000 Genome database. Based on the Hardy-Weinberg equilibrium, the calculated genetic prevalence of cystine stone disease is 1 in 30,585.Conclusion The clinical prevalence of cystine stone has been previously reported as 1 in 7,000, a notably higher figure than the genetic prevalence of 1 in 30,585 calculated in this study. This suggests that the etiology of cystine stone is more complex than what our current genetic knowledge can explain. Possible factors that may contribute to this difference include novel causal genes, undiscovered pathogenic variants, alternative inheritance models, founder effects, epigenetic modifications, environmental factors, or other modifying factors. Further investigation is needed to fully understand the etiology of cystine stone.Competing Interest StatementDr. Wilson Molina received grants from Boston Scientific and consulting fees from Boston scientific, IPG, Olympus, Johnson&Johnson in the past 36 months. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://www.internationalgenome.org/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.internationalgenome.org/